ストックスクリーナーアプリを入手
2.44
1.21%
-0.03
プレマーケット:
2.45
0.01
+0.41%
Nkarta Inc (NKTX) 最新ニュース
Nkarta's chief medical officer sells $19,003 in stock - MSN
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Nkarta executive sells shares worth $12,843 - MSN
Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India
Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com South Africa
Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia
Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat
JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa
Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa
Nkarta's chief technical officer sells $16,383 in stock - MSN
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Geode Capital Management LLC Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Franklin Resources Inc. Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc.: Trying To Find Space In A Crowded Place - Seeking Alpha
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Barclays PLC - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
State Street Corp Purchases 15,569 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $15.00 - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Fmr LLC Has $602,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
NKTX stock touches 52-week low at $2.22 amid market challenges - Investing.com
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase By Investing.com - Investing.com Australia
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase - Investing.com India
Citadel Advisors LLC's Strategic Acquisition of Nkarta Inc Shares - GuruFocus.com
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment By Investing.com - Investing.com South Africa
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment - Investing.com UK
Major Improvements In Nkarta Inc (NKTX) Stock Need To Be Considered - Stocks Register
Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment - TipRanks
Nkarta Announces IND Clearance of Investigator-Sponsored - GlobeNewswire
Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled - StockTitan
Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Sees Large Drop in Short Interest - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Brokerages - MarketBeat
Nkarta to Participate in an Upcoming Investor Conference - GlobeNewswire
Nkarta to Present NK Cell Therapy Advances at Evercore HealthCONx Conference | NKTX Stock News - StockTitan
4.81%
大文字化:
|
ボリューム (24 時間):